Arch Therapeutics, Inc. (ARTH)
USD 0.18
(10.43%)
USD 0.18
(10.43%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 9.46 Million USD | 39.28% |
| 2022 | 6.79 Million USD | 44.54% |
| 2021 | 4.7 Million USD | 28.77% |
| 2020 | 3.65 Million USD | -1.56% |
| 2019 | 3.7 Million USD | 6.59% |
| 2018 | 3.48 Million USD | -9.92% |
| 2017 | 3.86 Million USD | 94.81% |
| 2016 | 1.98 Million USD | -19.47% |
| 2015 | 2.46 Million USD | -68.3% |
| 2014 | 7.76 Million USD | 454.83% |
| 2013 | 1.4 Million USD | 22984.67% |
| 2012 | 6066.00 USD | 98.17% |
| 2011 | 3061.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 11.39 Million USD | 20.41% |
| 2024 Q3 | 13.95 Million USD | 12.41% |
| 2024 Q2 | 12.41 Million USD | 8.95% |
| 2023 Q1 | 7.6 Million USD | 11.89% |
| 2023 Q4 | 9.46 Million USD | -1.18% |
| 2023 FY | 9.46 Million USD | 39.28% |
| 2023 Q3 | 9.57 Million USD | 20.06% |
| 2023 Q2 | 7.97 Million USD | 4.92% |
| 2022 Q1 | 4.96 Million USD | 5.64% |
| 2022 FY | 6.79 Million USD | 44.54% |
| 2022 Q4 | 6.79 Million USD | 21.61% |
| 2022 Q2 | 4.49 Million USD | -9.43% |
| 2022 Q3 | 5.58 Million USD | 24.22% |
| 2021 FY | 4.7 Million USD | 28.77% |
| 2021 Q1 | 4.66 Million USD | 27.86% |
| 2021 Q2 | 4.8 Million USD | 2.83% |
| 2021 Q3 | 4.38 Million USD | -8.77% |
| 2021 Q4 | 4.7 Million USD | 7.35% |
| 2020 Q4 | 3.65 Million USD | 4.64% |
| 2020 FY | 3.65 Million USD | -1.56% |
| 2020 Q1 | 3.66 Million USD | -1.14% |
| 2020 Q2 | 3.43 Million USD | -6.46% |
| 2020 Q3 | 3.48 Million USD | 1.72% |
| 2019 Q3 | 3.96 Million USD | 50.8% |
| 2019 Q2 | 2.62 Million USD | -38.91% |
| 2019 Q1 | 4.3 Million USD | 23.58% |
| 2019 Q4 | 3.7 Million USD | -6.38% |
| 2019 FY | 3.7 Million USD | 6.59% |
| 2018 Q4 | 3.48 Million USD | -19.97% |
| 2018 Q2 | 1.39 Million USD | -27.84% |
| 2018 Q1 | 1.92 Million USD | -50.07% |
| 2018 Q3 | 4.34 Million USD | 212.42% |
| 2018 FY | 3.48 Million USD | -9.92% |
| 2017 Q4 | 3.86 Million USD | 31.43% |
| 2017 FY | 3.86 Million USD | 94.81% |
| 2017 Q3 | 2.93 Million USD | -1.93% |
| 2017 Q2 | 2.99 Million USD | 112.63% |
| 2017 Q1 | 1.4 Million USD | -28.92% |
| 2016 FY | 1.98 Million USD | -19.47% |
| 2016 Q4 | 1.98 Million USD | 1.29% |
| 2016 Q1 | 1.95 Million USD | -20.48% |
| 2016 Q3 | 1.95 Million USD | 19.26% |
| 2016 Q2 | 1.64 Million USD | -16.17% |
| 2015 Q3 | 9.38 Million USD | 43.58% |
| 2015 Q1 | 6.25 Million USD | -19.54% |
| 2015 FY | 2.46 Million USD | -68.3% |
| 2015 Q4 | 2.46 Million USD | -73.75% |
| 2015 Q2 | 6.53 Million USD | 4.55% |
| 2014 Q4 | 7.76 Million USD | -20.17% |
| 2014 FY | 7.76 Million USD | 454.83% |
| 2014 Q3 | 9.73 Million USD | -12.8% |
| 2014 Q2 | 11.16 Million USD | 651.45% |
| 2014 Q1 | 1.48 Million USD | 6.07% |
| 2013 Q1 | 6066.00 USD | 0.0% |
| 2013 Q3 | 419.26 Thousand USD | -86.7% |
| 2013 Q4 | 1.4 Million USD | 233.99% |
| 2013 Q2 | 3.15 Million USD | 51868.2% |
| 2013 FY | 1.4 Million USD | 22984.67% |
| 2012 FY | 6066.00 USD | 98.17% |
| 2012 Q1 | - USD | -100.0% |
| 2012 Q3 | 936.00 USD | 1434.43% |
| 2012 Q4 | 6066.00 USD | 548.08% |
| 2012 Q2 | 61.00 USD | 0.0% |
| 2011 FY | 3061.00 USD | 0.0% |
| 2011 Q4 | 3061.00 USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 72.47 Million USD | 86.938% |
| Neon Bloom, Inc. | 1.22 Million USD | -671.964% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -1070.375% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -21078.452% |
| Qrons Inc. | 1.48 Million USD | -535.846% |
| Rebus Holdings, Inc. | 5.24 Million USD | -80.578% |
| Skye Bioscience, Inc. | 14.07 Million USD | 32.733% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 83.96% |
| Adynxx, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -34405.599% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 87.365% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -4606.697% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 82.242% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 1.212% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -2145.408% |
| SQZ Biotechnologies Company | 50.03 Million USD | 81.083% |
| Intellipharmaceutics International Inc. | 12 Million USD | 21.175% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -145.777% |
| Mesoblast Limited | 188.44 Million USD | 94.977% |
| Marizyme, Inc. | 26.67 Million USD | 64.515% |
| Genus plc | 485 Million USD | 98.048% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -62.015% |
| Pharming Group N.V. | 244.07 Million USD | 96.122% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -370.911% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -276.18% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -149.103% |
| ContraFect Corporation | 32.53 Million USD | 70.902% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -377.761% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -147.304% |
| IMV Inc. | 37.93 Million USD | 75.046% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 19.632% |
| MultiCell Technologies, Inc. | 1617.67 USD | -585057.727% |
| ONE Bio Corp. | 27.49 Million USD | 65.573% |
| Accustem Sciences Inc. | 1.07 Million USD | -777.092% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 87.773% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -347.547% |
| Q BioMed Inc. | 8.13 Million USD | -16.39% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 88.586% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -83.946% |
| Biomind Labs Inc. | 1.49 Million USD | -531.646% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 92.027% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -4.686% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 48.564% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -560.17% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -6561.685% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -64.744% |
| GB Sciences, Inc. | 5.41 Million USD | -74.727% |
| Alpha Cognition Inc. | 7.16 Million USD | -32.118% |
| HST Global, Inc. | 593.59 Thousand USD | -1494.682% |
| CSL Limited | 18.62 Billion USD | 99.949% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -651.745% |
| Halberd Corporation | 728.71 Thousand USD | -1198.981% |
| Enzolytics Inc. | 365.26 Million USD | 97.409% |
| Agentix Corp. | 2.51 Million USD | -277.045% |
| Resverlogix Corp. | 67.39 Million USD | 85.955% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -1028.599% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 97.873% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -452.271% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 61.748% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 20.475% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -158.267% |
| AVAX Technologies, Inc. | 3.99 Million USD | -137.019% |
| Zenith Capital Corp. | 27.56 Thousand USD | -34235.38% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.286% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -3866.379% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -153.485% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -1290.342% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -249.085% |
| Kadimastem Ltd | 3.5 Million USD | -170.079% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -14043.228% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 81.168% |
| BioStem Technologies, Inc. | 15.9 Million USD | 40.483% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1937.001% |
| LadRx Corporation | 2.2 Million USD | -330.166% |
| Cell Source, Inc. | 15.8 Million USD | 40.115% |
| Regen BioPharma, Inc. | 5.45 Million USD | -73.444% |
| Regen BioPharma, Inc. | 5.45 Million USD | -73.444% |
| NovAccess Global Inc. | 7.86 Million USD | -20.42% |
| Affymax, Inc. | 8.87 Million USD | -6.706% |
| Itoco Inc. | 1.65 Million USD | -472.599% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -361.4% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -56.487% |
| Mobile Lads Corp. | 1.31 Million USD | -620.666% |
| CytoDyn Inc. | 127.89 Million USD | 92.599% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -22546.286% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -504.319% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 14.299% |
| SYBLEU INC | 681.41 Thousand USD | -1289.161% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -55.131% |
| International Stem Cell Corporation | 5.27 Million USD | -79.381% |
| Bioxytran, Inc. | 3.24 Million USD | -191.304% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -1412.589% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -105.018% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 76.91% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 57.485% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -367.364% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -72.799% |
| Neutra Corp. | 973.52 Thousand USD | -872.331% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 67.376% |
| PureTech Health plc | 125.58 Million USD | 92.462% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -151.946% |
| IXICO plc | 1.9 Million USD | -398.13% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 53.89% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 90.839% |
| CSL Limited | 18.62 Billion USD | 99.949% |
| Cellectis S.A. | 249.36 Million USD | 96.204% |